SCHEMBL30759683

SCHEMBL30759683

CC1(C)C(=O)NCCN1C(=O)c1nn(-c2ccccn2)c2c1CCc1ccc(-c3cccnc3)cc1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNA2 P20248 2/20 0.40
▸ CDK2 P24941 2/20 0.40
▸ CCNA1 P78396 2/20 0.40
▸ CYP11B2 P19099 11/20 0.37
▸ CYP11B1 P15538 9/20 0.37
▸ CYP19A1 P11511 4/20 0.37
▸ VHL P40337 1/20 0.37
▸ PIK3CD O00329 2/20 0.36
▸ PIK3R2 O00459 2/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ PIK3CB P42338 2/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ PIK3R5 Q8WYR1 2/20 0.36
▸ PIK3R3 Q92569 2/20 0.36
▸ TDP2 O95551 2/20 0.35
▸ MAP3K5 Q99683 1/20 0.34
▸ CYP1A2 P05177 4/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ TBXAS1 P24557 1/20 0.34
▸ PDE3B Q13370 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27125530 1.00 CCNA2 (0.40) CCNA2CDK2CCNA1CYP11B2CYP11B1
SCHEMBL27125685 0.92 CYP11B2 (0.36) CYP11B2CYP11B1CYP19A1PIK3CDPIK3R2
SCHEMBL30759654 0.92 CYP11B2 (0.36) CYP11B2CYP11B1CYP19A1PIK3CDPIK3R2
SCHEMBL27120798 0.91 CCNA2 (0.40) CCNA2CDK2CCNA1CYP11B2CYP11B1
SCHEMBL27120779 0.89 CCNA2 (0.42) CCNA2CDK2CCNA1CYP11B2PIK3CD
SCHEMBL27127851 0.88 CYP19A1 (0.41) CCNA2CDK2CCNA1CYP11B2CYP11B1
SCHEMBL30759605 0.88 CYP11B2 (0.35) CCNA2CDK2CCNA1CYP11B2CYP11B1
SCHEMBL27126008 0.88 VHL (0.35) CCNA2CDK2CCNA1CYP11B2CYP11B1
SCHEMBL30759704 0.88 VHL (0.35) CCNA2CDK2CCNA1CYP11B2CYP11B1
SCHEMBL27126549 0.88 CYP11B2 (0.35) CCNA2CDK2CCNA1CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008783-A1 MODULATORS OF FSHR AND USES THEREOF GEDEON RICHTER PLC (HU) 2026-01-08 — — US disclosed
EP-4577206-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF Celmatix Inc. (US) 2025-07-02 — — EP disclosed
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008783-A1 MODULATORS OF FSHR AND USES THEREOF FSHR, GNRHR, LHCGR CCNA2 2070/4885CDK2 1537/4885CCNA1 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback